Which mood stabilizers are FDA‑approved for children with bipolar disorder?

FDA-Approved Mood Stabilizers for Children

Lithium is the only mood stabilizer with FDA approval for children, specifically approved for ages 12 and older for both acute mania and maintenance therapy in bipolar disorder. 1

Current FDA Approval Status

Traditional Mood Stabilizers

• Lithium: FDA-approved from age 12 for acute mania and maintenance treatment 1
  • This remains the sole mood stabilizer with pediatric FDA approval, though the decision was historically based on adult literature rather than robust pediatric trials 1
  • In France, lithium is approved from age 16 2

Anticonvulsants (NOT FDA-Approved for Pediatric Bipolar Disorder)

Despite widespread clinical use, no anticonvulsant mood stabilizers have FDA approval for bipolar disorder in children or adolescents 1, 2:

• Valproate/Divalproex: No pediatric approval (approved only for adults with acute mania)
• Carbamazepine: No pediatric approval
• Lamotrigine: No pediatric approval

Atypical Antipsychotics (FDA-Approved but NOT Traditional Mood Stabilizers)

While technically antipsychotics rather than mood stabilizers, several have FDA approval for pediatric bipolar disorder 3, 4:

• Aripiprazole: Ages 10+ (US) or 13+ (France) for acute mania 2, 3
• Risperidone: Age 10+ for acute mania 2, 3
• Quetiapine: Age 10+ for acute mania 2, 3
• Olanzapine: Age 13+ for acute mania 2, 3

Critical Clinical Context

The evidence base for pediatric bipolar treatment remains sparse. 1 The AACAP guidelines explicitly state that lithium's FDA approval was granted "historically based on the adult literature" rather than comprehensive pediatric studies 1. Even the limited controlled trials of lithium in adolescents show concerning findings—one discontinuation study found high relapse rates in both lithium-treated and placebo groups, "raising questions about its ongoing efficacy" 1.

Common Clinical Pitfalls

1. Off-label anticonvulsant use is widespread but lacks FDA approval: Valproate, carbamazepine, and lamotrigine are commonly prescribed despite having no FDA approval for pediatric bipolar disorder 1, 2

2. Terminology confusion: Many clinicians refer to atypical antipsychotics as "mood stabilizers," but these are technically antimanic agents, not traditional mood stabilizers 1

3. Age restrictions vary by country: US approval starts at age 10-12 for most agents, while France requires age 13-16 2, 3

4. Safety monitoring is essential: Lithium requires regular blood tests due to narrow therapeutic window and nephrotoxicity risk; valproate carries hepatotoxicity and teratogenic risks; antipsychotics cause significant metabolic side effects more frequently in youth than adults 2

Real-World Prescribing Patterns

Epidemiologic data shows a disconnect between FDA approvals and actual practice: Anticonvulsants are prescribed more frequently than lithium in adolescents, despite lacking FDA approval, likely because prescribers fear lithium's risks from noncompliance or intentional overdose 2. Second-generation antipsychotics are increasingly preferred, though they carry substantial metabolic risks 5, 2.

Bottom line: If you need an FDA-approved mood stabilizer for a child with bipolar disorder, lithium (age 12+) is your only option. Everything else either lacks pediatric approval (anticonvulsants) or is technically an antipsychotic rather than a mood stabilizer.